Enzolytics Inc.
ENZC
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.17M
Close$
$-0.00
160% downside
Current Fair Value
160% downsideOvervalued by 160% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.17 Million |
|---|---|
| Enterprise Value | $261.86 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | 0.51 |
| Outstanding Shares | 3,444,470,933 |
Return
| Return on Equity | 0.34% |
|---|---|
| Return on Assets | -0.20% |
| Return on Invested Capital | 0.31% |
Valuation & Multiples
| P/E Ratio | -16.8 |
|---|---|
| PEG | -0.34 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -713.27 |
| Enterprise Value to Net Income | -649 |
| Total Debt to Enterprise | 0.99 |
| Debt to Equity | -2.19 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Enzolytics Inc.
1 employees
CEO: Steven Sharabura Enzolytics Inc., a biopharmaceutical company based in Plano, Texas, is dedicated to the development and commercialization of its specialized protein-based therapies. Its primary focus is on addressing severe infectious illnesses. The com...